Oxcarbazepine in Combination with Tiaprid in Inpatient Alcohol-withdrawal – a RCT

Abstract

Introduction: Oxcarbazepine (OXC), a derivative of Carbamazepine (CBZ), may represent a solution to metabolic and side effects of CBZ treatment due to the fact that renal excretion is its major route of elimination. The goal of the study is to compare the efficacy and tolerability of OXC/Tiaprid (TIA) combination therapy to the well established Clomethiazole (CLO) therapy in an inpatient setting.

Methods: To investigate the efficacy of OXC/TIA in terms of lower alcohol withdrawal symptoms and better tolerability, 56 alcohol-dependent patients participated in a randomized open-label trial, where OXC/TIA and CLO treatments were compared.

Results: Following admission, we observed that severity of alcohol withdrawal syndrome was comparable between OXC/TIA and CLO-patients. Overall tolerability was good. However, significantly more patients in the OXC/TIA-group (48.1%) displayed no AE compared to the CLO-group (24.1%). We found no significant differences between groups regarding total number of recorded adverse events (AEs).

Discussion: OXC/TIA inpatient therapy proved to be as effective and participants demonstrated the same tolerance as with CLO. In medication-based alcohol withdrawal, OXC/TIA could have the potential to become a promising alternative for alcohol dependent patients unable to undergo inpatient withdrawal therapy with CLO. Our findings further indicate that it could be worthwhile testing OXC/TIA in alcohol withdrawal in daily care units and outpatient settings. This is an important question for national health care services, since outpatient therapy is more and more asked for as alternative to inpatient settings.

References

• 1 Anton RF, Drobes DJ, Voronin K. et al . Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.  Psychopharmacology. 2004;  173 ((1–2)) 32-40
• 2 Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Second Edition, WHO/MSD/MSB/01.6a 2001
• 3 Beydoun A, Kutluay E. Oxcarbazepine.  Expert Opin Pharmacother. 2002;  3 59-71
• 4 Bock J. Determination of group sizes for biological experiments and controlled clinical trials [Bestimmung des Stichprobenumfangs für biologische Experimente und kontrollierte klinische Studien]. Oldenbourg, München 1998
• 5 Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism.  Expert Opin Investig Drugs. 2005;  14 371-376
• 6 Cazzato G, Gioseffi M, Torre P. et al . Prevention and therapy of delirium tremens with tiapride.  Riv Neurol. 1982;  52 379-391
• 7 Croissant B, Grosshans M, Klein O. et al . Scheme-based benzodiazepine detoxification with oxcarbazepine.  Pharmacopsychiatry. 2005;  38 222-223
• 8 Croissant B, Scherle T, Diehl A. et al . Oxcarbazepine in alcohol relapse prevention – A case series.  Pharmacopsychiatry. 2004;  37 306-307
• 9 Croissant B, Diehl A, Klein O. et al . A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.  Alcohol Clin Exp Res. 2006;  30 630-635
• 10 Finzen A. Medikamentenbehandlung bei psychischen Störungen. [Medication treatment of mental disorders]. Bonn: Psychiatrie-Verlag 1984
• 11 Franz M, Dlabal H, Kunz S. et al . Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazol.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 185-192
• 12 Furlanut M, Franceschi L, Poz D. et al . Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol.  Ther Drug Monit. 2006;  28 267-268
• 13 Glauser TA. Oxcarbazepine in the treatment of epilepsy.  Pharmacotherapy. 2001;  21 904-919
• 14 Gonzalez L, Veatch L, Ticku M. et al . Alcohol withdrawal kindling: mechanisms and implications for treatment.  Alcohol Clin Exp Res. 2001;  25 197-201
• 15 Hermann D, Klages E, Croissant B. Oxcarbazepine in outpatient benzodiazepine withdrawal in polytoxicomanic patients during an opiate maintenance therapy.  Psychopharmakotherap. 2005;  12 97-99
• 16 Hillemacher T, Weinland C, Heberlein A. et al . Treatment with clomethiazole is associated with lower rates of premature discharge during alcohol withdrawal.  Pharmacopsychiat. 2008;  41 134-137
• 17 Homberg V, Kowalik A, Schulze-Bonhage A. Ad hoc change from carbamazepine to oxcarbazepine – effectiveness and tolerance.  A retrospective analysis. Nervenarzt. 2001;  72 918-923
• 18 Koethe D, Juelicher A, Nolden BM. et al . Oxcarbazepine – efficacy and tolerability during treatment of alcohol withdrawal.  A double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res. 2007;  31 1188-1194
• 19 Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal.  N Engl J Med. 2003;  348 1786-1795
• 20 Littleton JM, De Witte P, Litten R. et al . Challenges to medications development in treating alcohol dependence: an international perspective.  Alcohol Alcohol. 2004;  39 ((4)) 271-275
• 21 Lucht M, Kuehn KU, Armbruster J. et al . Alcohol withdrawal treatment in intoxicated vs. non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam.  Alcohol Alcohol. 2003;  38 168-175
• 22 Lu BY, Coberly R, Bogenschutz M. Use of oxcarbazepine in outpatient alcohol detoxification.  Am J Addict. 2005;  14 191-192
• 23 Majumdar SK. Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome.  Drug Alcohol Depend. 1991;  27 201-207
• 24 Malcolm R, Lucht M, Kuehn KU. et al . Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.  Am J Psychiatry. 1989;  146 617-621
• 25 Malcolm R, Myrick H, Brady KT. et al . Update on anticonvulsants for the treatment of alcohol withdrawal.  Am J Addict. 2001;  10 16-23
• 26 Malcolm R, Myrick H, Roberts J. et al . The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.  J Gen Intern Med. 2002;  17 349-355
• 27 Mann K, Croissant B. Konzepte der Alkoholismustherapie [Concepts of Alcoholism Therapy]. In: Singer MV, Theyssen S, Herausgeber Alkohol und Alkoholfolgekrankheiten. Grundlagen – Diagnostik – Therapie [Alcohol and Alcohol Sequelae. Principles – Diagnostics – Therapy]. Berlin, Heidelberg, New York: Springer 2005: 509-518
• 28 Martinotti G, Nicola M Di, Romanelli R. et al . High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.  Hum Psychopharmacol. 2007;  22 149-156
• 29 Martinotti G, Romanelli R, Nicola M Di. et al . Oxcarbazepine at high dosages for the treatment of alcohol dependence.  Am J Addict. 2007;  16 247-248
• 30 Mayo-Smith MF. Pharmacological management of alcohol withdrawal.  A meta-analysis and evidence-based practice guideline. JAMA. 1997;  278 144-151
• 31 Murphy DJ, Shaw GK, Clarke I. Tiaprid and Chlormethiazole in alcohol withdrawal: a double-blind trail.  Alcohol Alcohol. 1983;  18 227-237
• 32 Peters DH, Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.  Drugs. 1994;  47 1010-1032
• 33 Ponce G, Rodriguez-Jimenez R, Ortiz H. et al . Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification.  Rev Neurol. 2005;  40 577-580
• 34 Ritola E, Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome.  Acta Psychiatr Scand. 1981;  64 254-259
• 35 Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient.  Drugs. 1998;  56 571-585
• 36 Schik G, Wedegaertner FR, Liersch J. et al . Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal.  Addict Biol. 2005;  10 283-288
• 37 Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?.  Epilepsy Behav. 2004;  5 627-635
• 38 Seifert J, Peters E, Jahn K. et al . Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance-a pilot study.  Addict Biol. 2004;  9 43-51
• 39 Shaw JM, Kolesar GS, Sellers EM. et al . Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care.  J Clin Psychopharmacol. 1981;  1 382-387
• 40 Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 197-200
• 41 Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence.  Pharmacopsychiatry. 2006;  39 30-34
• 42 Soyka M, Täschner B, Clausius N. Neuroleptic treatment of alcohol hallucinosis: case series.  Pharmacopsychiatry. 2007;  40 291-292
• 43 Sullivan JT, Sykora K, Schneiderman J. et al . Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).  Br J Addict. 1989;  84 1353-1357
• 44 Thome J, Wiesbeck GA, Vince GH. Carbamazepine in treatment of alcohol withdrawal syndrome – an overview of current research.  Fortschr Neurol Psychiatr. 1994;  62 125-133
• 45 Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy.  CNS Drugs. 2001;  15 137-163
• 46 Wetterling T, Veltrup C. Diagnostik und Therapie von Alkoholproblemen. Berlin: Springer Verlag 1997
• 47 Wetterling T, Weber B, Depfenhart M. et al . Development of a rating scale to predict the severity of withdrawal syndrome.  Alcohol Alcohol. 2006;  41 611-615

1 Work was conducted at Department of Internal Medicine, Diakoniekrankenhaus Mannheim GmbH, Teaching Hospital University of Heidelberg, Germany.

Correspondence